2018 IS SET TO BE THE YEAR THAT VIRTUAL REALITY COMES …€¦ · Bank of America Merrill Lynch...
4
MONTHLY INTELLIGENCE | CONFERENCES MONTHLY HEALTHCARE NEWSLETTER - DECEMBER 2017 A GLOBAL LEADER IN STRATEGIC HEALTHCARE COMMUNICATIONS London | New York | Boston | San Francisco Virtual reality (VR) is one of a new wave of emerging, immersive, technologies which is set to radically disrupt the healthcare sector. n recent years, VR studios have been producing all kinds of applications for all kinds of industries, but nowhere is the growth in VR stronger, or more justified, than in healthcare. To illustrate this, Professor Shafi Ahmed, ‘the VR Doctor’, recently used a mixed reality headset to plan an operation with specialists in Mumbai and London and then to aid communication – internationally – during the live operation. This allowed some of the world’s best specialists to be ‘virtually’ present at the same moment and share knowledge. The ability to operate or collaborate virtually in healthcare is the tip of a huge iceberg of the potential for VR to revolutionise the sector. Staying with the operating theatre, surgeons are able to gain training, performing virtual operations where they have force feedback, known as ‘haptics’, allowing them to understand when they have hit bone or are moving through softer tissues. They are able to take scans of patients prior to operations and then explore inside the body – via the scan – and understand the unique issues around each case before they even lift a scalpel. Parallel development with robotics will allow for virtual surgeries that use far more precision and dexterity than the human hand could ever achieve. However VR goes far beyond the operating theatre, with significant research being conducted into depression, anxiety, post- traumatic stress disorder (PTSD) and many more physiological applications. One particularly interesting study by UCL and ICREA (Catalan Institution for Research and Advanced Studies) allows patients with depression to enter a room in VR and try to calm a crying child in the corner. Their resulting efforts are fully captured from a full motion capture suit, allowing them to revisit the room, later in the week, and experience the same thing but from the perspective of the child. They are being soothed and calmed by a virtual version of themselves. For PTSD, technicians work with patients to try to recreate the moments that led to the stress. Amazingly this kind of exposure is (counter-intuitively) one of the best forms of treatment. Big Pharma has been moving fast into VR too. One of the largest areas of interest has been in disease awareness. AbbVie, for example, has produced an experience that simulates what it is like to have Parkinson’s disease, taking you through seemingly mundane real-life experiences such as shopping, and showing the complications and frustrations a condition such as Parkinson’s brings. One of the more innovative experiences is from GSK, which combined a VR headset with a pair of cameras, allowing you to see the world through the eyes of someone having a migraine, a truly frightening and eye-opening experience. Other experiences have focused on empathising with people with autism and epilepsy. Rehabilitation and physiotherapy also look set to benefit hugely from advances in VR. One of the most difficult parts of any recovery, be it from a stroke or a car crash, is the application of and sticking to a routine of laborious (and often very uncomfortable) exercises. What if you could make those exercises fun by putting on a headset and entering a game environment where doing your exercises earns you points? Your doctor could remotely monitor your progress, being alerted if your participation or achievement falls below a certain level. Those of us working in the VR space are seeing huge innovation and application of VR in healthcare – a whole industry is being developed which is going to significantly transform patient treatment, disease awareness, diagnosis and marketing. For more information on how VR could impact your business please visit http://visualise.com/ 2018 IS SET TO BE THE YEAR THAT VIRTUAL REALITY COMES OF AGE FOR HEALTHCARE HENRY STUART, CEO OF VISUALISE, PREDICTS THAT 2018 WILL BE THE YEAR THAT VR RESHAPES HEALTHCARE. AS WE PREPARE FOR MiFID II CHANGE ON 3 JANUARY PLEASE CONTACT CONSILIUM FOR INFORMATION OR VISIT OUR WEBSITE www.consilium-comms.com/news-insights/consilium-news
Transcript of 2018 IS SET TO BE THE YEAR THAT VIRTUAL REALITY COMES …€¦ · Bank of America Merrill Lynch...
MONTHLY INTELLIGENCE | CONFERENCES
MONTHLY HEALTHCARE NEWSLETTER - DECEMBER 2017A GLOBAL LEADER IN STRATEGIC HEALTHCARE COMMUNICATIONSLondon | New York | Boston | San Francisco
Virtual reality (VR) is one of a new wave of emerging, immersive, technologies which is set to radically disrupt the healthcare sector.
n recent years, VR studios have been producing all kinds of applications for all kinds of industries, but nowhere is the growth in VR stronger, or more justified, than in healthcare. To illustrate this, Professor Shafi Ahmed, ‘the VR Doctor’, recently used a mixed reality headset to plan an operation with specialists in Mumbai and London and then to aid communication – internationally – during the live operation. This allowed some of the world’s best specialists to be ‘virtually’ present at the same moment and share knowledge. The ability to operate or collaborate virtually in healthcare is the tip of a huge iceberg of the potential for VR to revolutionise the sector.
Staying with the operating theatre, surgeons are able to gain training, performing virtual operations where they have force feedback, known as ‘haptics’, allowing them to understand when they have hit bone or are moving through softer tissues. They are able to take scans of patients prior to operations and then explore inside the body – via the scan – and understand the unique issues around each case before they even lift a scalpel. Parallel development with robotics will allow for virtual surgeries that use far more precision and dexterity than the human hand could ever achieve.
However VR goes far beyond the operating theatre, with significant research being conducted into depression, anxiety, post-traumatic stress disorder (PTSD) and many more physiological applications. One particularly interesting study by UCL and ICREA (Catalan Institution for Research and Advanced Studies) allows patients with depression to enter a room in VR and try to calm a crying child in the corner. Their resulting efforts are fully captured from a full motion capture suit, allowing them to revisit the room, later in the week, and experience the same thing but from the perspective of the child.
They are being soothed and calmed by a virtual version of themselves. For PTSD, technicians work with patients to try to recreate the moments that led to the stress. Amazingly this kind of exposure is (counter-intuitively) one of the best forms of treatment.
Big Pharma has been moving fast into VR too. One of the largest areas of interest has been in disease awareness. AbbVie, for example, has produced an experience that simulates what it is like to have Parkinson’s disease, taking you through seemingly mundane real-life experiences such as shopping, and showing the complications and frustrations a condition such as Parkinson’s brings. One of the more innovative experiences is from GSK, which combined a VR headset with a pair of cameras, allowing you to see the world through the eyes of someone having a migraine, a truly frightening and eye-opening experience. Other experiences have focused on empathising with people with autism and epilepsy.
Rehabilitation and physiotherapy also look set to benefit hugely from advances in VR. One of the most difficult parts of any recovery, be it from a stroke or a car crash, is the application of and sticking to a routine of laborious (and often very uncomfortable) exercises. What if you could make those exercises fun by putting on a headset and entering a game environment where doing your exercises earns you points? Your doctor could remotely monitor your progress, being alerted if your participation or achievement falls below a certain level.
Those of us working in the VR space are seeing huge innovation and application of VR in healthcare – a whole industry is being developed which is going to significantly transform patient treatment, disease awareness, diagnosis and marketing.
For more information on how VR could impact your business please visit http://visualise.com/
2018 IS SET TO BE THE YEAR THAT VIRTUAL REALITY COMES OF AGE FOR HEALTHCAREHENRY STUART, CEO OF VISUALISE, PREDICTS THAT 2018WILL BE THE YEAR THAT VR RESHAPES HEALTHCARE.
AS WE PREPARE FOR MiFID II CHANGE ON 3 JANUARY PLEASE CONTACT CONSILIUM FOR INFORMATION OR VISIT OUR WEBSITE www.consilium-comms.com/news-insights/consilium-news
INVESTOR CONFERENCE EVENT CALENDAR
JANUARYBioTech Showcase 2018, San Francisco (8 – 10 January)JP Morgan Annual Healthcare Conference, San Francisco (8 – 11 January)ODDO BHF Forum, Lyon (11 – 12 January) BIA Gala Dinner, London (25 January)Future of Healthcare Investor Forum, London (25 January)
FEBRUARY Annual BIO CEO & Investor Conference, New York (12 – 13 February)Leerink Partners Global Healthcare Conference 2018, New York (14 – 15 February)RBC Capital Markets 2018 Healthcare Conference, New York (21 – 22 February) Annual European Life Science CEO Forum & Exhibition, Zurich (26 – 27 February) Annual JMP Securities Technology Research Conference, San Francisco (26 – 27 February) Credit Suisse Healthcare One-on-One Conference, London (27 – 28 February)
MARCH Cowen & Co. Annual Health Care Conference, Boston (5 – 7 March) Boston BioTech BD Conference, Boston (7 March) Roth Capital Partners Annual Conference, Orange County (11 – 14 March)BIO-Europe Spring, Amsterdam (12 – 14 March)Barclays Capital Healthcare Conference, Miami (13 – 15 March) Oppenheimer & Co. Annual Healthcare Conference, New York (20 – 21 March) Needham & Co. Annual Healthcare Conference, New York (27 – 28 March)KBC Securities Healthcare Conference, Brussels (TBD)
APRILKempen & Co Healthcare/Life Sciences Conference, Amsterdam (18 – 19 April) BioTrinity 2018 – European Biopartnering and Investment, London (23 – 25 April)
MAYDeutsche Bank Annual Healthcare Conference, Boston (8 – 9 May)Bank of America Merrill Lynch 2017 Healthcare Conference, Las Vegas (15 – 17 May)UBS Global Healthcare Conference, New York (21 – 23 May)
JUNEBIO 2018, Boston (4 – 7 June)Jefferies 2018 Global Healthcare Conference, New York (5 – 8 June)Goldman Sachs 38th Annual Global Healthcare Conference, Palos Verdes (13 – 15 June)JMP Securities Life Sciences Conference, New York (20 – 21 June)
JULY Citi European Healthcare Conference, London (TBD)
AUGUST Canaccord Genuity 38th Annual Growth Conference, Boston (8 – 9 August)
2018
MONTHLY INTELLIGENCE
MEDIA MOVES
• Gem Sosianos is now covering healthcare at Alliance News, replacing Hana Stewart-Smith who becomes news editor
SELL SIDE ANALYST MOVES
• Nick Turner is moving from Mirabaud to Prescient Healthcare Group
BANKING MOVES
• Bidhi Bhoma has moved from Shore Capital to Liberum
• Nick Moore will join Stifel from Jefferies
THIS MONTH’S MOVERS AND SHAKERS
COMPANY NAMEAMOUNT RAISED
TYPE OF FUNDRAISE COUNTRY DATE
PUBLIC COMPANY FINANCINGS
Orphazyme A/S $94.1 million IPO Denmark 16-Nov-17Mirati Therapeutics Inc. $80 million Follow-on US 16-Nov-17
Arsanis Inc. $60 millionIPO and Private
PlacementUS 16-Nov-17
Orphazyme A/S $94.1 million IPO Denmark 16-Nov-17Mirati Therapeutics Inc. $80 million Follow-on US 16-Nov-17
Arsanis Inc. $60 millionIPO and Private
PlacementUS 16-Nov-17
scPharmaceuticals Inc. $89.6 million IPO US 17-Nov-17Catalyst Pharmaceuticals Inc. $50 million Follow-on US 28-Nov-17Biocartis Group N.V. $94.4 million Private Placement Belgium 29-Nov-17Heron Therapeutics Inc. $150 million Follow-on US 5-Dec-17Advicenne Pharma S.A. $32.1 million IPO France 6-Dec-17Editas Medicine Inc. $50 million Follow-on US 7-Dec-17Revance Therapeutics Inc. $150 million Follow-on US 7-Dec-17GW Pharmaceuticals plc $276 million Follow-on UK 7-Dec-17ALK-Abelló A/S $111.5 million Private Placement Denmark 8-Dec-17Denali Therapeutics Inc. $250 million IPO US 8-Dec-17Odonate Therapeutics Inc. $150 million IPO US 8-Dec-17bluebird bio Inc. $600 million Follow-on US 13-Dec-17Blueprint Medicines Corp. $300 million Follow-on US 13-Dec-17argenx $231 million Follow-on US 14-Dec-17
PRIVATE COMPANY FINANCINGS
X4 Pharmaceuticals Inc. $27 million Series B US 16-Nov-17Step Pharma S.A.S. $10.2 million Series A France 21-Nov-17Medeor Therapeutics Inc. $57 million Series B US 27-Nov-173DMed $101.5 million Funding round China 28-Nov-17Mavupharma Inc. $20 million Series A US 29-Nov-17Codiak BioSciences Inc. $76.5 million Series C US 29-Nov-17Prognos $20.5 million Series C Switzerland 30-Nov-17resTORbio Inc. $40 million Series B US 30-Nov-17Semma Therapeutics Inc. $114 million Series B US 30-Nov-17GenomiCare Biotechnology Co. Ltd. Undisclosed Series A China 1-Dec-17Athyrium Capital Management L.P. $2 billion Third Fund US 2-Dec-17ChemomAb Ltd. $10 million Series B Israel 4-Dec-17Atox Bio Ltd. $30 million series F Israel 4-Dec-17Neon Therapeutics Inc. $36 million Series B US 5-Dec-17Qvella Corp. $20 million Series B Canada 5-Dec-17AmorChem L.P. $34.8 million Second Fund Canada 6-Dec-17MicuRx Pharmaceuticals Inc. $15.1 million Private Placement US 6-Dec-17Obsidian Therapeutics Inc. $49.5 million Series A US 6-Dec-17Metacrine Inc. $22 million Series B US 7-Dec-17
HIGHLIGHTED FUNDRAISING ACTIVITY FROM NOVEMBER TO DECEMBER 2017
Source: BioCentury
• Faron Pharmaceuticals appointed Juhana Heinonen as Chief Commercial Officer
• Alligator Bioscience appointed Charlotte Russell as CMO and Peter Ellmark as VP Discovery
• Teva’s CSO Michael Hayden has left the company
• Joerg Moeller appointed Head of R&D at Bayer
• Andreas Busch appointed as EVP, Head of R&D and CSO at Shire
• Biogen appointed Jeffrey Capello as CFO
• Juno Therapeutics appointed Ann Lee as EVP of Technical and Patrick Yang as EVP and Senior Adviser to the CEO
• Ironwood recruited William Huyett as COO and promoted Gina Consylman to SVP and CFO
• Gamida Cell named Julian Adams as CEO to replace Yael Margolin who is staying on as President
• Intrexon appointed Thomas Bostick as COO; promoted Nir Nimrodi to CBO; appointed Helen Sabzevari as President of Intrexon’s wholly owned subsidiary, Precigen
• Nektar Therapeutics made several promotions: Stephen Doberstein to SVP of R&D and Chief R&D Officer; Mary Tagliaferri to SVP of Clinical Development and CMO; and Jonathan Zalevsky to SVP of research and CSO
• Cleave Biosciences’ CEO Laura Shawver was appointed CEO of Synthorx
• Bruno Strigini, CEO of Novartis Oncology has retired
• Ergomed appoints Stephen Stamp as CEO and Jan Petracek as COO
If you would like to receive our Monday Healthcare Bulletin, which summarises all healthcare business news from the weekend, please contact: [email protected]
41 LOTHBURY | LONDON | EC2R 7HGNEW YORK | BOSTON | SAN FRANCISCO
+44 (0)20 3709 5700 [email protected] www.consilium-comms.com
FOR THE JP MORGAN 36TH ANNUAL
HEALTHCARE CONFERENCE
FROM ALL OF US HERE AT CONSILIUM STRATEGIC COMMUNICATIONS
WE LOOK FORWARD TO
SEEING YOU IN SAN FRANCISCO
HAPPY HOLIDAYS
8 - 11 JANUARY 2018
Please contact:[email protected]
